Safety and efficacy of oral TLR8 agonist, selgantolimod, in viremic adult patients with chronic hepatitis B

被引：0

作者：

Janssen, Harry L. A. ^{[1
]}

Lim, Young-Suk ^{[2
]}

Kim, Hyung Joon ^{[3
]}

Tseng, Cheng-Hao ^{[4
]}

Coffin, Carla S. ^{[5
]}

Elkashab, Magdy ^{[6
]}

Ahn, Sang Hoon ^{[7
]}

Anh-Hoa Nguyen ^{[8
]}

Chen, Diana ^{[8
]}

Wallin, Jeffrey ^{[8
]}

Tan, Susanna ^{[8
]}

Yang, Jenny ^{[8
]}

Gaggar, Anuj ^{[8
]}

Brainard, Diana ^{[8
]}

Fung, Scott ^{[1
]}

Kim, Yoon Jun ^{[9
,10
]}

Kao, Jia-Horng ^{[11
]}

Chuang, Wan-Long ^{[12
]}

Brooks, Anna ^{[13
,14
]}

Dunbar, P. Rod ^{[13
,14
]}

机构：

[1] Univ Hlth Network, Toronto Gen Hosp Res Inst, Toronto Ctr Liver Dis, Toronto, ON, Canada

[2] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[3] Chung Ang Univ, Coll Med, Seoul, South Korea

[4] E Da Hosp, Kaohsiung, Taiwan

[5] Univ Calgary, Cumming Sch Med, Calgary, AB, Canada

[6] Toronto Liver Ctr, Toronto, ON, Canada

[7] Yonsei Univ, Coll Med, Seoul, South Korea

[8] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[9] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[10] Seoul Natl Univ Hosp, Liver Res Inst, Seoul, South Korea

[11] Natl Taiwan Univ Hosp, Taipei, Taiwan

[12] Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan

[13] Univ Auckland, Sch Biol Sci, Auckland, New Zealand

[14] Univ Auckland, Maurice Wilkins Ctr Auckland, Auckland, New Zealand

来源：

JOURNAL OF HEPATOLOGY | 2021年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

PO-2429

引用

页码：S757 / S758

页数：2

共 50 条

[1] Safety and Efficacy of Oral TLR8 Agonist, Selgantolimod, in Viremic Adult Patients With Chronic Hepatitis B
Janssen, Harry
Lim, Young-Suk
Kim, Hyung Joon
Tseng, Cheng-Hao
Coffin, Carla
Elkashab, Magdy
Ahn, Sang Hoon
Nguyen, Anh-Hoa
Chen, Diana
Wallin, Jeffrey
Tan, Susana
Yang, Jenny
Gaggar, Anuj
Brainard, Diana
Fung, Scott
Kim, Yoon Jun
Kao, Jia-Horng
Chuang, Wan-Long
Brooks, Anna
Dunbar, Rod
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S865 - S865
[2] SAFETY AND EFFICACY OF 24 WEEKS TREATMENT WITH ORAL TLR8 AGONIST, SELGANTOLIMOD, IN VIREMIC ADULT PATIENTS WITH CHRONIC HEPATITIS B: A PHASE 2 STUDY
Janssen, Harry L. A.
Lim, Young-Suk
Kim, Hyung Joon
Tseng, Cheng-Hao
Coffin, Carla S.
Elkhashab, Magdy
Ahn, Sang Hoon
Nguyen, Anh-Hoa
Chen, Diana
Wallin, Jeffrey
Tan, Susanna
Yang, Jenny C.
Gagger, Anuj
Brainard, Diana M.
Fung, Scott K.
Kim, Yoon Jun
Kao, Jia-Horng
Chuang, Wan-Long
[J]. HEPATOLOGY, 2020, 72 : 506A - 507A
[3] Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B
Gane, Edward J.
Kim, Hyung Joon
Visvanathan, Kumar
Kim, Yoon Jun
Anh-Hoa Nguyen
Wallin, Jeffrey J.
Chen, Diana Y.
McDonald, Circe
Arora, Priyanka
Tan, Susanna K.
Gaggar, Anuj
Roberts, Stuart K.
Lim, Young-Suk
[J]. HEPATOLOGY, 2021, 74 (04) : 1737 - 1749
[4] Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression
Gane, Edward J.
Dunbar, P. Rod
Brooks, Anna E.
Zhang, Fangqiu
Chen, Diana
Wallin, Jeffrey J.
van Buuren, Nicholas
Arora, Priyanka
Fletcher, Simon P.
Tan, Susanna K.
Yang, Jenny C.
Gaggar, Anuj
Kottilil, Shyamasundaran
Tang, Lydia
[J]. JOURNAL OF HEPATOLOGY, 2023, 78 (03) : 513 - 523
[5] Efficacy and safety of 24 weeks treatment with oral TLR8 agonist, selgantolimod, in virally-suppressed adult patients with chronic hepatitis B: a phase 2 study
Gane, Edward
Dunbar, P. Rod
Brooks, Anna
Zhao, Yang
Tan, Susanna
Lau, Audrey
Yang, Jenny
Gaggar, Anuj
Subramanian, Mani
Kottilil, Shyamasundaran
Tang, Lydia
[J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S52 - S52
[6] Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators
Amin, Oliver E.
Colbeck, Emily J.
Daffis, Stephane
Khan, Shahzada
Ramakrishnan, Dhivya
Pattabiraman, Divya
Chu, Ruth
Steuer, Holly Micolochick
Lehar, Sophie
Peiser, Leanne
Palazzo, Adam
Frey, Christian
Davies, Jessica
Javanbakht, Hassan
Rosenberg, William M. C.
Fletcher, Simon P.
Maini, Mala K.
Pallett, Laura J.
[J]. HEPATOLOGY, 2021, 74 (01) : 55 - 71
[7] Oral Selective TLR8 Agonist Selgantolimod Induces Multiple Immune Cell Responses in Humans
Ayithan, Natarajan
Ghosh, Alip
Dwivedi, Ankit
Wallin, Jeffrey J.
Tan, Susanna K.
Chen, Diana
Kottilil, Shyam
Poonia, Bhawna
[J]. VIRUSES-BASEL, 2021, 13 (12):
[8] Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection
Janssen, Harry L.
Lim, Young-Suk
Kim, Hyung Joon
Sowah, Leonard
Tseng, Cheng-Hao
Coffin, Carla S.
Elkhashab, Magdy
Ahn, Sang Hoon
Nguyen, Anh-Hoa
Chen, Diana
Wallin, Jeffrey J.
Fletcher, Simon P.
McDonald, Circe
Yang, Jenny C.
Gaggar, Anuj
Brainard, Diana M.
Fung, Scott
Kim, Yoon Jun
Kao, Jia-Horng
Chuang, Wan-Long
Brooks, Anna E.
Dunbar, P. Rod
[J]. JHEP REPORTS, 2024, 6 (02)
[9] CHARACTERIZATION OF CYTOKINE RESPONSE TO TOLL RECEPTOR 8 AGONIST SELGANTOLIMOD (SLGN) IN VIREMIC AND VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB)
Chen, Diana
McDonald, Circe
Tan, Susanna
Yang, Jenny
Gane, Edward J.
Janssen, Harry L. A.
Kottilil, Shyam
Tang, Lydia
Coffin, Carla S.
Ahn, Sang Hoon
Kim, Hyung Joon
Kim, Yoon Jun
Lim, Young-Suk
Chuang, Wan-Long
Kao, Jia-Horng
Tseng, Cheng-Hao
Gaggar, Anuj
Wallin, Jeffrey
[J]. HEPATOLOGY, 2020, 72 : 437A - 438A
[10] EFFICACY AND SAFETY OF ORAL TLR8 AGONIST GS-9688 IN VIRALLY-SUPPRESSED ADULT PATIENTS WITH CHRONIC HEPATITIS B: A PHASE 2, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, MULTI-CENTER STUDY
Gane, Edward J.
Zhao, Yang
Tan, Susanna
Lau, Audrey H.
Gaggar, Anuj
Subramanian, Mani
Kottilil, Shyam
Tang, Lydia
[J]. HEPATOLOGY, 2019, 70 : 435A - 436A

← 1 2 3 4 5 →